New developments in atherosclerosis: clinical potential of PCSK9 inhibition
Ilaria Giunzioni, Hagai Tavori Knight Cardiovascular Institute, Center for Preventive Cardiology, Oregon Health and Science University, Portland, OR, USA Abstract: Pro-protein convertase subtilisin/kexin type 9 (PCSK9) is a secreted 692-amino acid protein that binds surface low-density lipoprotein...
| Main Authors: | , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Dove Medical Press
2015-08-01
|
| Series: | Vascular Health and Risk Management |
| Online Access: | http://www.dovepress.com/new-developments-in-atherosclerosis-clinical-potential-of-pcsk9-inhibi-peer-reviewed-article-VHRM |